Sponsor & Developer Portfolio

GSK

Clinical development pipeline, platform architecture, and registered trial tracking for GSK vaccine candidates.

Candidates

Target Diseases

Linked Studies

Development Phase Distribution

Discontinued / Inactive: 24 Phase 3 Clinical Trial: 10 Phase 2 Clinical Trial: 8 Phase 1 Clinical Trial: 5 Approved / Licensed: 2

Platform Technologies

Biological (unspecified platform): 39 Conjugate vaccine: 3 mRNA: 3 See FDA product page / label: 2 Protein / subunit: 1 Viral vector: 1

Target Pathogens & Indications

COVID-19 Diarrhoea Diphtheria / Tetanus / Pertussis HPV Hepatitis A Hepatitis B Herpes Simplex Influenza Lung Cancer, Non-Small Cell Malaria Measles / Mumps / Rubella Melanoma Meningococcal disease Pneumococcal disease RSV Rabies Rotavirus Salmonella Infections Streptococcal Infections Tuberculosis Typhoid Varicella / Zoster

Vaccine Pipeline Candidates (49)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

View Global Pipeline Matrix →

Approved / Licensed fda-arexvy

AREXVY

Target: RSV

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication

View Full Clinical Profile → Disease Hub →

Approved / Licensed fda-priorix

PRIORIX

Target: Measles / Mumps / Rubella

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-diphtheria-tetanus-pertussis-hepatitis-b-hib-vaccine-glaxosmithk

Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: See linked ClinicalTrials.gov records for primary completion dates

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk-bio-s-influenza-vaccine-gsk2584786a-different-formulations-g

GSK Bio's influenza vaccine GSK2584786A, different formulations

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2011-03-22 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk-biologicals-investigational-h1n1-influenza-vaccine-gsk234027

GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2010-10 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk-biologicals-investigational-tb-vaccine-gsk-692342-glaxosmith

GSK Biologicals' investigational TB vaccine GSK 692342

Target: Tuberculosis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2014-04-01 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-gsk-influenza-virus-h5n1-vaccine-1557484a-glaxosmithkline

GSK influenza virus H5N1 vaccine 1557484A

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2013-02 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk-pandemic-vaccine-gsk2340272a-glaxosmithkline

GSK pandemic vaccine GSK2340272A

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2011-01-14 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk-s-candidate-influenza-vaccine-1562902a-glaxosmithkline

GSK's candidate influenza vaccine 1562902A

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2011-07 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk1572932a-antigen-specific-cancer-immunotherapeutic-glaxosmith

GSK1572932A Antigen-Specific Cancer Immunotherapeutic

Target: Lung Cancer, Non-Small Cell

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2013-12-06 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-gsk2202083a-vaccine-glaxosmithkline

GSK2202083A vaccine

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2009-06-25 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk2231395a-glaxosmithkline

GSK2231395A

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2009-04-07 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-gsk2340272a-gsk-biologicals-investigational-influenza-pandemic-v

GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2010-11-25 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-cervarix-glaxosmithkline

Havrix

Target: HPV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2012-01-16 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-havrix-glaxosmithkline

Havrix®

Target: Hepatitis A

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-01-28 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-immunotherapeutic-gsk2132231a-glaxosmithkline

Immunotherapeutic GSK2132231A

Target: Melanoma

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2014-11-17 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-infanrix-ipv-hib-glaxosmithkline

Infanrix-IPV/Hib

Target: Influenza

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2018-08-01 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-investigational-h7n9-vaccine-gsk3277510a-glaxosmithkline

Investigational H7N9 vaccine GSK3277510A

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2016-06 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-lower-dose-formulation-of-hsv-vaccine-gsk4108771a-glaxosmithklin

Lower dose formulation of HSV vaccine (GSK4108771A)

Target: Herpes Simplex

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-05-26 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-chad155-hii-hbv-low-dose-formulation-glaxosmithkline

MVA-HBV low dose formulation

Target: Hepatitis B

Platform: Viral vector

Key Milestone: Primary completion (most advanced trial): 2024-10-07 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-pandemrixtm-glaxosmithkline

PandemrixTM

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2011-02 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-rsv-mat-glaxosmithkline

RSV MAT

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2023-11-06 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-rsv-vaccine-gsk3003891a-formulation-1-glaxosmithkline

RSV vaccine (GSK3003891A) formulation 1

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2017-07-14 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-rabipur-glaxosmithkline

Rabipur

Target: Rabies

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-05-12 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-251154-vaccine-glaxosmithkline

Synflorix™

Target: Rotavirus

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2012-08 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-undecavalent-pneumococcal-protein-d-conjugate-vaccine-glaxosmith

undecavalent pneumococcal-protein D conjugate vaccine

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2004-06 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-investigational-rsv-vaccine-1-glaxosmithkline

Investigational RSV vaccine 1

Target: RSV

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-04-13 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-investigational-mrna-seasonal-flu-covid-19-combination-flu-covm-

Licensed Seasonal Influenza Vaccine

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-12-03 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-low-dose-strep-a-alum-glaxosmithkline

Low dose Strep A Alum

Target: Streptococcal Infections

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-11-30 (registry estimate)

View Full Clinical Profile →

Phase 1 Clinical Trial ctgov-pn-maps30plus-glaxosmithkline

Pn-MAPS30plus

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-02-22 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-pan-salmonella-with-alum-low-dose-vaccine-glaxosmithkline

Typhoid Vi conjugate vaccine

Target: Salmonella Infections

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-11-14 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-adjuvanted-rsvpref3-vaccine-glaxosmithkline

Adjuvanted RSVPreF3 vaccine

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-01-12 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-flu-mrna-formulation-b1-glaxosmithkline

Flu mRNA(Formulation A)

Target: Influenza

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-07-31 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-ints-gmma-dose-c-glaxosmithkline

MenACWY

Target: Typhoid

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-09-30 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-altsonflex1-2-3-glaxosmithkline

Menveo

Target: Diarrhoea

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-10-31 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-ped-hz-su-glaxosmithkline

PED-HZ/su

Target: Varicella / Zoster

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-05-01 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-rts-s-as01e-vaccine-glaxosmithkline

RTS,S/AS01E vaccine

Target: Malaria

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-04-23 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-low-dose-of-ints-tcv-glaxosmithkline

TYPHIBEV

Target: Typhoid

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-04-27 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-rsv-hmpv-v-low-dose-vaccine-glaxosmithkline

hMPV_Y low dose vaccine

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2029-04-05 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-hz-su-vaccine-glaxosmithkline

HZ/su vaccine

Target: Varicella / Zoster

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-08-23 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-mmrvns-glaxosmithkline

MMRV

Target: Measles / Mumps / Rubella

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-02-28 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-investigational-varicella-vaccine-glaxosmithkline

Marketed varicella vaccine

Target: Varicella / Zoster

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-11-23 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-investigational-varicella-vaccine-lot-1-glaxosmithkline

Marketed varicella vaccine_Lot 1

Target: Varicella / Zoster

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-12-25 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-rsvpref3-oa-vaccine-glaxosmithkline

Placebo

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-09-25 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-rsvpref3-oa-investigational-vaccine-glaxosmithkline

RSVPreF3 OA investigational vaccine

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2022-06-06 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-recombinant-zoster-vaccine-glaxosmithkline

Recombinant zoster vaccine

Target: Varicella / Zoster

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2030-04-01 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-dtpa-glaxosmithkline

dTpa

Target: Diphtheria / Tetanus / Pertussis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-12-11 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-dtpa-vaccine-glaxosmithkline

dTpa vaccine

Target: Diphtheria / Tetanus / Pertussis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-10-14 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-rmenb-omv-nz-glaxosmithkline

rMenB+OMV NZ

Target: Meningococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-09-07 (registry estimate)

View Full Clinical Profile → Disease Hub →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →